<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574390</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00082277</org_study_id>
    <nct_id>NCT02574390</nct_id>
  </id_info>
  <brief_title>Answer ALS: Individualized Initiative for ALS Discovery</brief_title>
  <acronym>AnswerALS</acronym>
  <official_title>Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York Genome Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leandro P. Rizzuto Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Neurology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University Les Turner ALS Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Creation of a large repository of induced pluripotent stem cells (iPSC), bio-fluid samples
      (blood and spinal fluid (optional)), and cell lines for ALS gene identification. This will be
      combined carefully with collected measures of the pattern of the symptoms people with ALS
      have and how these change over time. People with other motor neuron diseases and healthy
      controls will be included as comparisons
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will have 5 study visits; screening, 3, 6, 9 and 12 months. There will be a one year
      post-participation follow-up period, during which they will receive an email or phone call
      interview once every 3 months. During the first year, samples will be collected, breathing,
      muscle strength, spasticity, general function and cognitive behavior will be assessed.
      Healthy controls will have 2 study visits during which blood samples will be collected and
      questionnaires given.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>ALS Functional Rating Scale-Revised (ALSFRS-R)</measure>
    <time_frame>once every 3 months for one year</time_frame>
    <description>12 questions about patient's ability to function in certain activities of daily living. Each question is out of 4 with 4 being normal and 0 being completely impaired.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ALS Cognitive Behavioral Scale (ALS-CBS)</measure>
    <time_frame>once every 3 months for one year</time_frame>
    <description>short measure of cognition and behavior in patients with ALS. The cognitive portion consists of 8 tasks with a perfect score being 20. The behavioral portion measures changes in personality and behavior since the onset of ALS symptoms as well as mood, pseudobulbar affect and fatigue and is completed by a family member or caregiver. A normal score is 45.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slow Vital Capacity (SVC)</measure>
    <time_frame>once every 3 months for one year</time_frame>
    <description>measurement of the maximum amount of air that can be exhaled following a deep breath.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Strength Testing with Hand Held Dynamometer (HHD)</measure>
    <time_frame>once every 3 months for one year</time_frame>
    <description>muscle strength testing performed on upper and lower limbs, ankles, wrists and fingers using a small hand held device. These measurements are followed over time and compared to measure decline.</description>
  </primary_outcome>
  <enrollment type="Actual">1049</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Primary Lateral Sclerosis</condition>
  <condition>Flail Arm ALS</condition>
  <condition>Progressive Muscular Atrophy</condition>
  <condition>Monomelic Amyotrophy</condition>
  <condition>Motor Neuron Disease</condition>
  <condition>Asymptomatic ALS Gene Carriers</condition>
  <condition>Healthy Controls</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, serum, DNA, Cerebrospinal fluid, induced pluripotent stem cells,
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with ALS, Primary Lateral Sclerosis Flail Arm ALS Progressive Muscular Atrophy
        Monomelic Amyotrophy Motor Neuron Disease Asymptomatic ALS Gene Carriers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with familial or sporadic ALS diagnosed as possible, laboratory-supported
             probable, probable or definite according to the World Federation of Neurology (WFN) El
             Escorial criteria, Primary Lateral Sclerosis Flail Arm ALS, Progressive Muscular
             Atrophy, Monomelic Amyotrophy, Motor Neuron Disease, Asymptomatic ALS Gene Carriers

          -  Participants who are ages 18-100, inclusive.

        Exclusion Criteria:

          -  Participants with Spinal-Bulbar Muscular Atrophy

          -  Known diagnosis of HIV/AIDS, Hepatitis B, or Hepatitis C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas J Maragakis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James D Berry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Generel Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Neurology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 9, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2015</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>stem cell</keyword>
  <keyword>biomarker</keyword>
  <keyword>disease progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

